Hospital Readmissions Among Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Arformoterol or Fluticasone/Salmeterol

被引：0
|
作者：
Stensland, Mike [1 ]
Bollu, Vamsi [1 ]
Donohue, James [1 ]
机构：
[1] Agile Outcomes Res Inc, Rochester, MN USA
来源：
CHEST | 2015年 / 148卷 / 04期
关键词：
D O I：
10.1378/chest.2278614
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
716A
引用
收藏
页数：2
相关论文
共 50 条
  • [31] How to reduce hospital readmissions in chronic obstructive pulmonary disease?
    Raghavan, Deepa
    Bartter, Thaddeus
    Joshi, Manish
    CURRENT OPINION IN PULMONARY MEDICINE, 2016, 22 (02) : 106 - 112
  • [32] Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Arformoterol Following a Respiratory Event
    Navaie, M.
    Ganapathy, V.
    Gilmer, T. P.
    Xu, Z.
    Cho-Reyes, S.
    Celli, B. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [33] Efficacy of indacaterol as a single therapy versus salmeterol/fluticasone therapy in patients with milder chronic obstructive pulmonary disease
    Ruxandra, Ulmeanu
    Antoniu, Sabina Antonela
    Mihaltan, Florin
    Boisteanu, Daniela
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (10) : 1539 - 1541
  • [34] Arrhythmias in Patients With Chronic Obstructive Pulmonary Disease (COPD) Occurrence Frequency and the Effect of Treatment With the Inhaled Long-Acting Beta2-Agonists Arformoterol and Salmeterol
    Hanrahan, John P.
    Grogan, Donna R.
    Baumgartner, Rudolf A.
    Wilson, Amy
    Cheng, Hailong
    Zimetbaum, Peter J.
    Morganroth, Joel
    MEDICINE, 2008, 87 (06) : 319 - 328
  • [35] Efficacy and Safety Analysis of Salmeterol/Fluticasone Propionate with Tiotropium Bromide for Chronic Obstructive Pulmonary Disease
    Zhang, Zili
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 86 : 128 - 133
  • [36] COMPARING COSTS AND CONSEQUENCES OF TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH BUDESONIDE/FORMOTEROL AND FLUTICASONE/SALMETEROL
    Roggeri, A.
    Pantaleoni, M.
    Pasina, C.
    Inzillo, V
    Roggeri, D. P.
    VALUE IN HEALTH, 2013, 16 (07) : A371 - A371
  • [37] Reducing Readmissions for Chronic Obstructive Pulmonary Disease in Response to the Hospital Readmissions Reduction Program
    Myers, Laura C.
    Cash, Rebecca
    Liu, Vincent X.
    Camargo, Carlos A., Jr.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2021, 18 (09) : 1506 - 1513
  • [38] Effects of Tiotropium and Salmeterol/Fluticasone Propionate on Airway Wall Thickness in Chronic Obstructive Pulmonary Disease
    Hoshino, Makoto
    Ohtawa, Junichi
    RESPIRATION, 2013, 86 (04) : 280 - 287
  • [39] Interleukin-32, not reduced by salmeterol/fluticasone propionate in smokers with chronic obstructive pulmonary disease
    Du Yipeng
    Wang Wei
    Yang Wei
    He Bei
    CHINESE MEDICAL JOURNAL, 2014, 127 (09) : 1613 - 1618
  • [40] Interleukin-32, not reduced by salmeterol/fluticasone propionate in smokers with chronic obstructive pulmonary disease
    Du Yipeng
    Wang Wei
    Yang Wei
    He Bei
    中华医学杂志(英文版), 2014, (09) : 1613 - 1618
12345